Vij Puneet, Hussain Mohammad Shabir, Satapathy Sanjaya K, Cobos Everardo, Tripathi Manish K
Department of Pharmaceutical Sciences, St. John's University, Queens, NY 11439, USA.
Medicine and Oncology ISU, School of Medicine, The University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
Cancers (Basel). 2024 Nov 21;16(23):3904. doi: 10.3390/cancers16233904.
Hepatocellular carcinoma (HCC), a liver cancer originating from hepatocytes, is a major health concern and among the most common malignancies worldwide. Sorafenib, approved by the U.S. F.D.A., is the primary first-line treatment for patients with advanced HCC. While the preferred first-line systemic regimen for HCC is immunotherapy with Atezolizumab plus bevacizumab or Tremelimumab-actl + durvalumab, Sorafenib is still an alternative recommended regimen. While some patients with advanced HCC may benefit from Sorafenib treatment, most eventually develop resistance, leading to poor prognosis. Long noncoding RNAs (lncRNAs) have been found to play a critical role in tumorigenesis and the development of HCC, as well as other cancers. They are also key players in tumor drug resistance, though the mechanisms of lncRNAs in Sorafenib resistance in HCC remain poorly understood. This review summarizes the molecular mechanisms contributing to Sorafenib resistance in HCC with their potential correlation with lncRNAs, including the roles of transporters, receptors, cell death regulation, and other influencing factors.
肝细胞癌（HCC）是一种起源于肝细胞的肝癌，是一个主要的健康问题，也是全球最常见的恶性肿瘤之一。索拉非尼已获美国食品药品监督管理局批准，是晚期HCC患者的主要一线治疗药物。虽然HCC首选的一线全身治疗方案是阿替利珠单抗联合贝伐单抗或曲美木单抗-actl+度伐利尤单抗进行免疫治疗，但索拉非尼仍是推荐的替代方案。虽然一些晚期HCC患者可能从索拉非尼治疗中获益，但大多数最终会产生耐药性，导致预后不良。长链非编码RNA（lncRNAs）已被发现在肿瘤发生以及HCC和其他癌症的发展中起关键作用。它们也是肿瘤耐药的关键因素，尽管lncRNAs在HCC对索拉非尼耐药中的机制仍知之甚少。本综述总结了导致HCC对索拉非尼耐药的分子机制及其与lncRNAs的潜在关联，包括转运体、受体、细胞死亡调节和其他影响因素的作用。
